In addition, it has been demonstrated that NGS analysis of genes such as FGFR3, ERBB2, ERCC2, and TMB (proposed treatment response markers in simple tissue) offers a cost-effective and minimally invasive strategy for stratifying patients in clinical trials, which constitutes a new line of application in the field of precision medicine in cancer [101]. The gene discussed is ERBB2; the disease is cancer.